193
Participants
Start Date
March 8, 2012
Primary Completion Date
April 8, 2024
Study Completion Date
April 8, 2024
Certolizumab Pegol (CZP)
"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
Certolizumab Pegol (CZP)
"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
Ra0043 87, New York
Ra0043 85, New Hyde Park
Ra0043 81, Washington D.C.
Ra0043 76, Durham
Ra0043 74, Charlotte
Ra0043 70, Avon
Ra0043 78, Cleveland
Ra0043 95, Cleveland
Ra0043 73, Cincinnati
Ra0043 75, Indianapolis
Ra0043 82, Chicago
Ra0043 90, Chicago
Ra0043 71, Little Rock
Ra0043 84, San Francisco
Ra0043 89, Portland
Ra0043 79, Los Angeles
Ra0043 83, Hartford
Ra0043 80, Hackensack
Ra0043 77, Livingston
Ra0043 86, Columbus
RA0043 2, Buenos Aires
Ra0043 15, Curitiba
Ra0043 14, Porto Alegre
Ra0043 12, São Paulo
Ra0043 21, Calgary
Ra0043 22, Montreal
Ra0043 20, Toronto
Ra0043 60, Santiago
Ra0043 32, Mexico City
Ra0043 31, México
Ra0043 30, Monterrey
Ra0043 33, San Luis Potosí City
Ra0043 41, Moscow
Ra0043 43, Moscow
Ra0043 40, Saint Petersburg
Ra0043 42, Tolyatti
Collaborators (1)
PRA Health Sciences
INDUSTRY
UCB BIOSCIENCES GmbH
INDUSTRY